{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:39:11Z","timestamp":1790764751295,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.critrevonc.2021.103350","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T22:32:24Z","timestamp":1620772344000},"page":"103350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Critical review of oncology clinical trial design under non-proportional hazards"],"prefix":"10.1016","volume":"162","author":[{"given":"Revathi","family":"Ananthakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Previtali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LaValley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103350_bib0005","series-title":"Survival Analysis Using SAS: A Practical Guide","author":"Allison","year":"2010"},{"key":"10.1016\/j.critrevonc.2021.103350_bib0010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2021.103350_bib0015","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.7314\/APJCP.2015.16.17.7923","article-title":"Fitting cure rate model to breast cancer data of Cancer Research Center","volume":"16","author":"Baghestani","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"15","key":"10.1016\/j.critrevonc.2021.103350_bib0020","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/sim.2517","article-title":"Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over","volume":"25","author":"Barthel","year":"2006","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103350_bib0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/19466315.2020.1755722","article-title":"The hazards of period specific and weighted hazard ratios","volume":"12","author":"Bartlett","year":"2020","journal-title":"Stat. Biopharm. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103350_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jval.2017.07.008","article-title":"Accounting for uncertainty in decision analytic models using rank preserving structural failure time modeling: application to parametric survival models","volume":"21","author":"Bennett","year":"2018","journal-title":"Value Health"},{"issue":"October (17)","key":"10.1016\/j.critrevonc.2021.103350_bib0035","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103350_bib0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cmpb.2013.10.001","article-title":"An R-package for estimating sample size of proportional hazards mixture cure model","volume":"113","author":"Cai","year":"2014","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2051-1426-1-18","article-title":"Statistical issues and challenges in immuno-oncology","volume":"1","author":"Chen","year":"2013","journal-title":"Int. J. Immunother. Cancer Res."},{"issue":"May (18)","key":"10.1016\/j.critrevonc.2021.103350_bib0050","doi-asserted-by":"crossref","first-page":"29925","DOI":"10.18632\/oncotarget.15557","article-title":"A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"Feburary","key":"10.1016\/j.critrevonc.2021.103350_bib0055","first-page":"24","article-title":"Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics","author":"Ding","year":"2020","journal-title":"Pharm. Stat."},{"issue":"Suppl 5","key":"10.1016\/j.critrevonc.2021.103350_bib0060","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.09.004","article-title":"Mechanism of action of immunotherapy","volume":"41","author":"Disis","year":"2014","journal-title":"Semin. Oncol."},{"issue":"June (3)","key":"10.1016\/j.critrevonc.2021.103350_bib0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1740774520905563","article-title":"Designing clinical trials with (restricted) mean survival time endpoint: practical considerations","volume":"17","author":"Eaton","year":"2020","journal-title":"Clin. Trials"},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2021.103350_bib0070","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1177\/0962280220907355","article-title":"K-sample omnibus non-proportional hazards tests based on right-censored data","volume":"29","author":"Gorfine","year":"2020","journal-title":"Stat. Methods Med. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103350_bib0075","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/pst.1609","article-title":"Sample size determination for the weighted log-rank test with the Fleming\u2013Harrington class of weights in cancer vaccine studies","volume":"13","author":"Hasegawa","year":"2014","journal-title":"Pharm. Stat."},{"issue":"May (3)","key":"10.1016\/j.critrevonc.2021.103350_bib0080","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/pst.1846","article-title":"Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point","volume":"17","author":"Huang","year":"2018","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0085","series-title":"Bayesian Survival Analysis. Springer Series in Statistics","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3447-8_5","article-title":"Cure rate models","author":"Ibrahim","year":"2001"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103350_bib0090","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jval.2017.09.010","article-title":"Effect of crossover in oncology clinical trials on evidence levels in early benefit assessment in Germany","volume":"21","author":"Isbary","year":"2018","journal-title":"Value Health"},{"issue":"Jul-Sep (3)","key":"10.1016\/j.critrevonc.2021.103350_bib0095","first-page":"1184","article-title":"Application of accelerated failure time models for breast cancer patients\u2019 survival in Kurdistan Province of Iran","volume":"12","author":"Karimi","year":"2016","journal-title":"J. Cancer Res. Ther."},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2021.103350_bib0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamacardio.2017.2922","article-title":"Restricted mean survival time as a measure to interpret clinical trial results","volume":"2","author":"Kim","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2021.103350_bib0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103350_bib0110","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1586\/14737167.2015.1037835","article-title":"Treatment switching in oncology trials and the acceptability of adjustment methods","volume":"15","author":"Latimer","year":"2015","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0115","article-title":"Adjusting for treatment switching in randomised controlled trials\u2014A simulation study and a simplified two-stage method","author":"Latimer","year":"2014","journal-title":"Stat. Methods Med. Res."},{"issue":"April (3)","key":"10.1016\/j.critrevonc.2021.103350_bib0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0272989X13520192","article-title":"Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations","volume":"34","author":"Latimer","year":"2014","journal-title":"Med. Decis. Mak."},{"issue":"Jan (3)","key":"10.1016\/j.critrevonc.2021.103350_bib0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1017\/S026646231600026X","article-title":"Treatment switching: statistical and decision-making challenges and approaches","volume":"32","author":"Latimer","year":"2016","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.critrevonc.2021.103350_bib0130","article-title":"Assessing methods for dealing with treatment switching in clinical trials: a follow-up simulation study","author":"Latimer","year":"2016","journal-title":"Stat. Methods Med. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103350_bib0135","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/cam4.643","article-title":"Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy","volume":"5","author":"Latimer","year":"2016","journal-title":"Cancer Med."},{"issue":"March (1)","key":"10.1016\/j.critrevonc.2021.103350_bib0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12874-019-0709-9","article-title":"Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring","volume":"19","author":"Latimer","year":"2019","journal-title":"BMC Med. Res. Methodol."},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2021.103350_bib0145","article-title":"Statistical inference methods for two crossing survival curves: a comparison of methods","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103350_bib0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/10543406.2018.1534857","article-title":"Estimation of delay time in survival data with delayed treatment effect","volume":"29","author":"Li","year":"2019","journal-title":"J. Biopharm. Stat."},{"issue":"September 8","key":"10.1016\/j.critrevonc.2021.103350_bib0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.conctc.2017.09.004","article-title":"Estimation of treatment effects in weighted log-rank tests","author":"Lin","year":"2017","journal-title":"Contemp. Clin. Trials Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103350_bib0160","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103350_bib0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/19466315.2019.1697738","article-title":"Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis","volume":"12","author":"Lin","year":"2020","journal-title":"Stat. Biopharm. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103350_bib0170","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/19466315.2020.1825522","article-title":"Rejoinder to letter to the editor \u201cThe hazards of period specific and weighted hazard ratios\u201d","volume":"12","author":"Lin","year":"2020","journal-title":"Stat. Biopharm. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103350_bib0175","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/10543406.2012.678528","article-title":"Analysis of time-to-event data with nonuniform patient entry and loss to follow-up under a two-stage seamless adaptive design with weibull distribution","volume":"22","author":"Lu","year":"2012","journal-title":"J. Biopharm. Stat."},{"issue":"Septemver (20)","key":"10.1016\/j.critrevonc.2021.103350_bib0180","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/sim.8186","article-title":"Modestly weighted logrank tests","volume":"38","author":"Magirr","year":"2019","journal-title":"Stat. Med."},{"issue":"September","key":"10.1016\/j.critrevonc.2021.103350_bib0185","first-page":"20","article-title":"Survival analysis using a 5-step stratified testing and amalgamation routine (5-STAR) in randomized clinical trials","author":"Mehrotra","year":"2020","journal-title":"Stat. Med."},{"issue":"Sep (10)","key":"10.1016\/j.critrevonc.2021.103350_bib0190","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"suppl_5","key":"10.1016\/j.critrevonc.2021.103350_bib0195","first-page":"v605","article-title":"LBA50 - Overall Survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: updated results from PROFILE 1014","volume":"28","author":"Mok","year":"2017","journal-title":"Ann. Oncol."},{"issue":"July (14)","key":"10.1016\/j.critrevonc.2021.103350_bib0200","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-11-2859","article-title":"Cure models as a useful statistical tool for analyzing survival","volume":"18","author":"Othus","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2021.103350_bib0205","article-title":"Interpretability of Cancer Clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol."},{"issue":"Dec (12)","key":"10.1016\/j.critrevonc.2021.103350_bib0210","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1177\/0962280220931560","article-title":"Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials","volume":"29","author":"Prior","year":"2020","journal-title":"Stat. Methods Med. Res."},{"issue":"15_suppl (May 20)","key":"10.1016\/j.critrevonc.2021.103350_bib0215","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.1200\/JCO.2018.36.15_suppl.6617","article-title":"Immunotherapy (IO) versus non-IO for oncology drugs: comparing survival benefits (SB) using restricted mean survival time","volume":"36","author":"Rahmadian","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"February (4)","key":"10.1016\/j.critrevonc.2021.103350_bib0220","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2010.34.2808","article-title":"Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?","volume":"30","author":"Rimawi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0225","article-title":"Delayed treatment effects, treatment switching and heterogeneous patient populations: how to design and analyze RCTs in oncology","author":"Ristl","year":"2020","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0230","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1080\/03610929108830654","article-title":"Correcting for non-compliance in randomized trials using rank preserving structural failure time models","volume":"20","author":"Robins","year":"1991","journal-title":"Commun. Stat. Theory Methods"},{"key":"10.1016\/j.critrevonc.2021.103350_bib0235","article-title":"Robust design and analysis of clinical trials with non-proportional hazards: a straw man guidance from a cross-pharma working group","author":"Roychoudhury","year":"2021","journal-title":"Stat. Biopharm. Res."},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2021.103350_bib0240","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/1536867X1701700209","article-title":"A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome","volume":"17","author":"Royston","year":"2017","journal-title":"Stata J."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103350_bib0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1536867X1801800102","article-title":"Power and sample-size analysis for the Royston\u2013Parmar combined test in clinical trials with a time-to-event outcome","volume":"18","author":"Royston","year":"2018","journal-title":"Stata J."},{"issue":"December (13)","key":"10.1016\/j.critrevonc.2021.103350_bib0250","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"7","author":"Royston","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"issue":"August (15)","key":"10.1016\/j.critrevonc.2021.103350_bib0255","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1745-6215-15-314","article-title":"An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect","volume":"7","author":"Royston","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.critrevonc.2021.103350_bib0260","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12874-016-0110-x","article-title":"Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated","volume":"16","author":"Royston","year":"2016","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0265","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13063-019-3251-5","article-title":"Combined test versus logrank\/Cox test in 50 randomised trials","volume":"20","author":"Royston","year":"2019","journal-title":"Trials"},{"issue":"April (1)","key":"10.1016\/j.critrevonc.2021.103350_bib0270","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s13063-020-4153-2","article-title":"A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome","volume":"21","author":"Royston","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.critrevonc.2021.103350_bib0275","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1214\/aos\/1176349395","article-title":"Some new estimators for cox regression","volume":"21","author":"Sasieni","year":"1993","journal-title":"Ann. Stat."},{"issue":"Issue 1, April","key":"10.1016\/j.critrevonc.2021.103350_bib0280","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/biomet\/68.1.316","article-title":"The asymptotic properties of nonparametric tests for comparing survival distributions","volume":"Volume 68","author":"Schoenfeld","year":"1981","journal-title":"Biometrika"},{"issue":"Jul (20)","key":"10.1016\/j.critrevonc.2021.103350_bib0285","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","article-title":"Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"28","author":"Sparano","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103350_bib0290","first-page":"190","article-title":"Accelerated failure time models provide a useful statistical framework for aging research.Exp Gerontol","volume":"44","author":"Swindell","year":"2009","journal-title":"Mar"},{"key":"10.1016\/j.critrevonc.2021.103350_bib0295","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3923\/jas.2014.609.616","article-title":"Cure rate models: a review of recent progress with a study of change-point cure models when cured is partially known","volume":"14","author":"Taweab","year":"2014","journal-title":"J. Appl. Sci."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0300","series-title":"Sample Size Calculation Based on the Semiparametric Analysis of the Short-term and Long-term Hazard Ratios","author":"Wang","year":"2013"},{"issue":"29","key":"10.1016\/j.critrevonc.2021.103350_bib0305","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1002\/sim.5465","article-title":"Sample size calculation for the proportional hazards cure model","volume":"31","author":"Wang","year":"2012","journal-title":"Stat. Med."},{"issue":"Nov-Dec (6)","key":"10.1016\/j.critrevonc.2021.103350_bib0310","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/pst.1602","article-title":"Adjusting overall survival for treatment switches: commonly used methods and practical application","volume":"12","author":"Watkins","year":"2013","journal-title":"Pharm. Stat."},{"issue":"March (6)","key":"10.1016\/j.critrevonc.2021.103350_bib0315","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/sim.8440","article-title":"Cancer immunotherapy trial design with cure rate and delayed treatment effect","volume":"39","author":"Wei","year":"2020","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0320","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/00002030-199708000-00008","article-title":"Impact of treatment changes on the interpretation of the Concorde trial","volume":"11","author":"White","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.critrevonc.2021.103350_bib0325","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1002\/(SICI)1097-0258(19991015)18:19<2617::AID-SIM187>3.0.CO;2-E","article-title":"Randomisation-based methods for correcting for treatment changes: examples from the Concorde trial","volume":"18","author":"White","year":"1999","journal-title":"Stat. Med."},{"issue":"Feburary (4)","key":"10.1016\/j.critrevonc.2021.103350_bib0330","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/sim.7157","article-title":"Designing therapeutic cancer vaccine trials with delayed treatment effect","volume":"36","author":"Xu","year":"2017","journal-title":"Stat. Med."},{"issue":"30","key":"10.1016\/j.critrevonc.2021.103350_bib0335","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1002\/sim.7937","article-title":"Designing cancer immunotherapy trials with random treatment time-lag effect","volume":"37","author":"Xu","year":"2018","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0340","doi-asserted-by":"crossref","first-page":"583","DOI":"10.29220\/CSAM.2017.24.6.583","article-title":"Diagnostics for the cox model","volume":"24","author":"Xue","year":"2017","journal-title":"CSAM"},{"key":"10.1016\/j.critrevonc.2021.103350_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/biomet\/92.1.1","article-title":"Semiparametric analysis of short-term and long-term hazard ratios with two-sample survival data","volume":"92","author":"Yang","year":"2005","journal-title":"Biometrika"},{"issue":"March (1)","key":"10.1016\/j.critrevonc.2021.103350_bib0350","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1541-0420.2009.01243.x","article-title":"Improved logrank-type tests for survival data using adaptive weights","volume":"66","author":"Yang","year":"2010","journal-title":"Biometrics"},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2021.103350_bib0355","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/biostatistics\/kxq061","article-title":"Estimation of the 2-sample hazard ratio function using a semiparametric model","volume":"12","author":"Yang","year":"2011","journal-title":"Biostatistics"},{"issue":"May (11)","key":"10.1016\/j.critrevonc.2021.103350_bib0360","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/sim.6453","article-title":"Assessing potentially time-dependent treatment effect from clinical trials and observational studies for survival data, with applications to the Women\u2019s Health Initiative combined hormone therapy trial","volume":"34","author":"Yang","year":"2015","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2021.103350_bib0365","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1467-9469.2012.00804.x","article-title":"Checking the short-term and long-term hazard ratio model for survival data","volume":"39","author":"Yang","year":"2012","journal-title":"Scand. J. Stat."},{"issue":"December (4)","key":"10.1016\/j.critrevonc.2021.103350_bib0370","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/biom.12916","article-title":"A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect","volume":"74","author":"Ye","year":"2018","journal-title":"Biometrics"},{"key":"10.1016\/j.critrevonc.2021.103350_bib0375","article-title":"Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards","author":"Yung","year":"2019","journal-title":"Biometrics"},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2021.103350_bib0380","first-page":"1095","article-title":"A comparison between accelerated failure-time and cox proportional hazard models in analyzing the survival of gastric cancer patients","volume":"44","author":"Zare","year":"2015","journal-title":"Iran. J. Public Health"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:38:18Z","timestamp":1760902698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821001384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":76,"alternative-id":["S1040842821001384"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103350","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical review of oncology clinical trial design under non-proportional hazards","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103350"}}